Abstract
EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mu......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
